Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: SC Palliation of prostatic carcinoma 3.6 mg every 28 days or 10.8 mg every 12 wk. Pituitary desensitisation before ovulation induction w/ gonadotrophins Depot 3.6 mg.
Hypersensitivity; pregnancy, lactation.
Special Precautions
Urinary tract obstruction or spinal cord compression (when used for prostate cancer); decreased bone density in women. Contraceptive measures should be taken to protect against pregnancy. Monitor men at risk from tumour flare during the 1st mth of therapy. Safety and efficacy on the usage of the 10.8 mg implant in women is not established.
Adverse Reactions
Vaginal bleeding and dryness, arthralgia, paraesthesias, increase in menstrual bleeding, hot flushes, sexual dysfunction. Headache, emotional lability, depression, insomnia, diaphoresis, dizziness, breast swelling/tenderness, Inj site reactions. Anaphylaxis.
ROUTE(S) : SC: D In patients w/ advanced breast cancer
ROUTE(S) : SC: X In patients w/ endometriosis & endometrial thinning
ATC Classification
L02AE03 - goserelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy.
Disclaimer: This information is independently developed by CIMS based on goserelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in